ADVM Adverum Biotechnologies Inc.

+0.93  (+7%)
Previous Close 12.47
Open 12.52
Price To Book 4.86
Market Cap 863,753,709
Shares 64,459,232
Volume 1,520,604
Short Ratio
Av. Daily Volume 1,130,493

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted November 1, 2018.
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
Wet age-related macular degeneration (Wet-AMD)
Phase 1 24-Week data from first cohort to be presented September 12, 2019.
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
  2. Edited Transcript of ADVM earnings conference call or presentation 8-Aug-19 8:30pm GMT
  3. The Keys to Successful Timing the Markets - August 15, 2019
  4. Adverum Biotechnologies, Inc. (ADVM) Q2 2019 Earnings Call Transcript
  5. Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
  6. Adverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  7. What's in the Cards for Perrigo (PRGO) This Earnings Season?
  8. Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
  9. Adverum Biotechnologies Announces Board and Senior Management Changes
  10. Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy?
  11. 2 Top Stocks to Buy in August
  12. Is the Options Market Predicting a Spike in Adverum (ADVM) Stock?
  13. Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates
  14. What Makes Adverum Biotechnologies (ADVM) a New Strong Buy Stock
  15. Adverum Biotechnologies Appoints Senior Leaders
  16. 3 Top Growth Stocks to Buy Right Now
  17. 5 Best Biotech Stocks of 2019 So Far
  18. Adverum (ADVM) Jumps: Stock Rises 5.1%
  19. Adverum Biotechnologies to Present Data at Upcoming Conferences
  20. 3 Biotechs That Have Doubled This Year (Acquisition Next?)